AIFM2 and acute lymphoblastic leukemia: This makes ALL cells sensitive to compounds targeting the GSH pathway, while overexpression of FSP1 can enhance resistance and promote tumor growth, revealing the metabolic vulnerability and therapeutic potential of ALL (80).